Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of LY2409021 in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GLBG
- Sponsors Eli Lilly and Company
- 26 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 13 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.